Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Shattuck Labs, Inc. has received an average recommendation of "Moderate Buy" from five research firms, with price targets ranging from $2.00 to $4.00.
• Insider activity shows significant investment, with Director Orbimed Advisors purchasing over 6 million shares at an average cost of $0.87, increasing their ownership by 600%.
• Shattuck Labs reported earnings of ($0.24) EPS for the last quarter, surpassing analyst expectations by $0.01.

Shares of Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $3.00.

Several equities research analysts recently issued reports on the company. Needham & Company LLC reiterated a "hold" rating on shares of Shattuck Labs in a report on Thursday, August 14th. Wedbush began coverage on Shattuck Labs in a report on Monday, September 8th. They issued an "outperform" rating and a $4.00 price objective on the stock. Wall Street Zen upgraded Shattuck Labs from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Finally, Leerink Partners lowered their target price on Shattuck Labs from $4.00 to $2.00 and set an "outperform" rating on the stock in a report on Thursday, August 14th.

Shattuck Labs Trading Down 0.4%

STTK stock opened at $2.37 on Friday. Shattuck Labs has a 12-month low of $0.69 and a 12-month high of $2.49. The stock has a market cap of $113.52 million, a price-to-earnings ratio of -1.96 and a beta of 1.89. The business's 50-day moving average is $1.41 and its 200 day moving average is $1.11.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.01. As a group, equities analysts forecast that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Insider Activity at Shattuck Labs

In related news, Director Orbimed Advisors Llc bought 6,306,127 shares of the stock in a transaction dated Monday, August 25th. The shares were acquired at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the acquisition, the director directly owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mona Ashiya bought 6,306,127 shares of the stock in a transaction dated Monday, August 25th. The shares were bought at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the completion of the acquisition, the director owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. The trade was a -600.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.00% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE raised its position in shares of Shattuck Labs by 135.0% during the 4th quarter. Bank of America Corp DE now owns 187,089 shares of the company's stock valued at $226,000 after buying an additional 107,491 shares during the period. Millennium Management LLC raised its position in shares of Shattuck Labs by 37.0% during the 4th quarter. Millennium Management LLC now owns 201,214 shares of the company's stock valued at $243,000 after buying an additional 54,322 shares during the period. Nuveen LLC purchased a new stake in shares of Shattuck Labs during the 1st quarter valued at approximately $50,000. ADAR1 Capital Management LLC purchased a new stake in shares of Shattuck Labs during the 1st quarter valued at approximately $97,000. Finally, AQR Capital Management LLC raised its position in shares of Shattuck Labs by 265.4% during the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock valued at $41,000 after buying an additional 31,355 shares during the period. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.